3 Healthcare Stocks Paying the Highest Dividends of 2026

Pfizer's forward-looking dividend yield is about 6.5% after revenues slid from a ~2022 peak just over $100B to struggling to keep annual sales above $60B; the company targets several potential blockbuster drugs by 2030. Dentsply Sirona yields just over 5% and has more than doubled its per-share dividend over the past decade, indicating faster dividend growth. Bristol Myers Squibb yields just over 4%, has raised its dividend for 17 consecutive years, and is supporting ~50 compounds in clinical trials while legacy drugs remain cash cows.

Analysis

Pfizer: the latent asset is not just the pipeline but the optionality embedded in capacity and regulatory relationships. If 2–3 late‑stage oncology or specialty approvals land within 12–36 months, revenue mix can re‑leverage quickly because existing biomanufacturing slots and global regulatory pathways shorten commercial ramp timelines; conversely, a cluster of near‑term trial misses would compress valuation much faster than cash flow due to the current high option value in the shares.

Dentsply Sirona (XRAY): think of this as a cash‑flow compounder tied to replacement cycles, reimbursement tick rates, and practice consolidation rather than a pure growth story. Margins respond asymmetrically — incremental share gain in consumables scales earnings faster than equipment sales do — so a modest acceleration in practice consolidation or insurance coverage expansion can drive outsized free cash flow over 2–4 years, while an elective‑care pullback would bite within quarters.

Bristol Myers Squibb and incumbent big pharmas: their primary role is volatility dampener. Stable franchises finance optionality, but this also makes them vulnerable to underappreciated binary risks (biosimilar entries, adverse safety signals) that can create multi‑quarter drawdowns despite steady cash generation. Watch regulatory/court calendars and major readout windows as the decisive catalysts that will re‑price relative multiples across the group.

Key Decisions for Investors

• PFE: Tactical LEAP asymmetric — buy 18–30 month calls (e.g., Jan 2028 strikes near current spot) sized 1–3% portfolio notional and fund by selling 6–9 month calls (~30–40% delta) to reduce cost. R/R: if 2+ late‑stage wins, target 2–4x on premium; downside capped to net premium/assignment risk if funded calls are exercised.
• XRAY: Core long with income overlay — accumulate on 5–15% pullbacks to a 1–2% portfolio weight and sell consecutive 3–6 month covered calls to harvest yield while waiting for consolidation/consumables re‑acceleration. R/R: expect 20–35% total return over 12–36 months if practice consolidation trends continue; downside ~20–30% in severe elective spend shock.
• Pair (event): Long PFE / Short BMY equal notionals over 12–24 months to play asymmetric outcome of idiosyncratic pipelines — this isolates pipeline re‑rating vs defensive cash flow. R/R: aims for net 25–50% if PFE pipeline outperforms and BMY remains rangebound; risk is persistent correlation and BMY defensive outperformance, cap pair size to <2% net exposure.
• Risk control: set explicit stop/bucket limits — for option trades limit premium loss to 100% of paid; for equity positions use 20–30% hard stops or hedge with index put spreads during major readout windows to protect against correlated sector selloffs.